Breaking News
May 23, 2018 - Researchers identify mechanisms that regulate mammary gland development
May 23, 2018 - ‘Low-Alcohol’ Booze Labels May Backfire
May 23, 2018 - New research shows that children with autism are able to create imaginary friends
May 23, 2018 - New technology could make prosthetic use more intuitive and reliable
May 23, 2018 - Researchers develop injectable bandage to stop fatal blood loss, activate wound healing
May 23, 2018 - Exercising for 4-5 days per week is needed to keep the heart young
May 23, 2018 - New study unravels secrets of HIV’s persistence
May 23, 2018 - IDF launches initiative to improve health services for displaced people with diabetes
May 23, 2018 - DNA vaccine shows promise for colorectal cancer
May 23, 2018 - Abnormal brain connections seen in preschoolers with autism
May 23, 2018 - Study finds increase in number of calls to US Poison Control Centers about ADHD medication exposures
May 23, 2018 - Yoghurt before a meal packed with health benefits
May 23, 2018 - New tool predicts the lifetime risk of Alzheimer’s
May 23, 2018 - Scientists reveal mechanisms that may help preterm infants extend nephron development window
May 23, 2018 - Unnecessary antibiotic use for asthma exacerbations linked to increased hospital stays, costs
May 23, 2018 - Quitting cigarettes linked to better lung health than long-term light smoking
May 23, 2018 - Researchers shed light on how androgen deprivation therapy increases risk for cardiovascular mortality
May 23, 2018 - Ingesting blue dye tablet during colonoscopy aids in detecting difficult-to-see polyps
May 23, 2018 - Patients with low-back pain benefit from early physical therapy
May 23, 2018 - Researchers discover link between tuberculosis and Parkinson’s disease
May 23, 2018 - FDA Approves Doptelet (avatrombopag) for Chronic Liver Disease Patients with Thrombocytopenia who are Undergoing a Medical Procedure
May 23, 2018 - Is knee pain linked to depression?
May 23, 2018 - Research team uncovers new information that more accurately explains formation of tumors
May 23, 2018 - Brain stimulation shows promise in treating obesity by reducing food cravings
May 23, 2018 - Mediterranean diet may protect people from negative effects of air pollution
May 23, 2018 - Researcher aims to develop virtual biopsy tool for early melanoma detection
May 23, 2018 - Medical centers more willing to perform lung transplants for severe alcoholic hepatitis patients
May 23, 2018 - The brain may tune to social learning even at rest, finds study
May 23, 2018 - Eczema drug alleviates asthma symptoms and improves lung function
May 23, 2018 - Researchers to test two-pronged approach in humans to treat advanced colorectal cancer
May 23, 2018 - FDA Alert: Juluca, Tivicay, Triumeq (dolutegravir): FDA to Evaluate
May 23, 2018 - Neuroscientists say daily ibuprofen can prevent Alzheimer’s disease
May 23, 2018 - Scientists decipher workings of little-understood bacterial riboswitch
May 23, 2018 - Investigational drug offers hope of relief for celiac disease patients exposed to gluten
May 23, 2018 - PCI along with prescribed drugs better than medication alone for treating for people with heart disease
May 23, 2018 - ToolGen’s CRISPR/Cas9 gene editing platform improves T-cell anti-tumor activity in mouse model
May 22, 2018 - FDA approves new drug to treat thrombocytopenia in adults with chronic liver disease
May 22, 2018 - CSIRO study urges Australians to avoid junk protein foods for healthy weight loss
May 22, 2018 - Breath Test Shows Promise for Diagnosis of Esophagogastric CA
May 22, 2018 - Common class of drugs linked to dementia even when taken 20 years before diagnosis
May 22, 2018 - Optimal Biomarker Frequency for Biosensors
May 22, 2018 - Ethics of conducting clinical research during public health emergencies
May 22, 2018 - FDA Approves Aimovig (erenumab), The First Drug Aimed at Preventing Migraines
May 22, 2018 - Warning labels on alcohol containers highly deficient, new research shows
May 22, 2018 - Doctors publish comprehensive proposal to ensure universal access to safe, affordable medications
May 22, 2018 - When is insurance not really insurance? When you need pricey dental care.
May 22, 2018 - Thyroid tumors may be more susceptible to precisely targeted radiation treatment, suggests study
May 22, 2018 - Researchers uncover clues to early lung transplant failure
May 22, 2018 - Coagulation Factor Tests: MedlinePlus Lab Test Information
May 22, 2018 - Booze ads cause risky drinking in young people
May 22, 2018 - Are you and your primary care doc ready to talk about your DNA?
May 22, 2018 - UCI research team uncovers new unexpected mode of neurotransmitter-based communication
May 22, 2018 - Researcher develops nanoparticle-based tags to detect viruses and cancer with high sensitivity
May 22, 2018 - Researchers highlight need for transgender-inclusive healthcare providers
May 22, 2018 - Celgene to share new and updated data around novel hematological therapies
May 22, 2018 - Scientists identify cell types underlying schizophrenia
May 22, 2018 - ACR urges legislative action on access and cost barriers in rheumatologic care
May 22, 2018 - Study examines link between nicotine dependence and likelihood to quit smoking after lung cancer screening
May 22, 2018 - Experts highlight the need to move beyond conventional cost-effectiveness analysis
May 22, 2018 - PanOptica doses first patient in Phase 1/2 dose-ranging clinical trial of PAN-90806
May 22, 2018 - New report highlights danger of childhood drowning in open water
May 22, 2018 - Proposed definition of patient-centeredness and engagement in healthcare
May 22, 2018 - Scientists reveal likely cause of childhood leukaemia
May 22, 2018 - Specific patterns of fat distribution linked to metabolic disease, shows study
May 22, 2018 - Novel drug prevents memory impairment in mice exposed to simulated deep space radiation
May 22, 2018 - New LIVE scoring tool effectively predicts future risk of hospitalization for COPD patients
May 22, 2018 - Most people with preclinical signs of Alzheimer’s disease may not develop dementia
May 22, 2018 - Fetal MRI can accurately identify holoprosencephaly by 18 weeks of gestation
May 22, 2018 - Multidisciplinary clinic can provide quality care for low-income patients with lung conditions
May 22, 2018 - Researchers create tool to determine patient’s response to immunotherapy drugs
May 22, 2018 - Pfizer starts Phase 1/2 study of RSV vaccine candidate in healthy adult volunteers
May 22, 2018 - New technique allows researchers to control heart cells growing in a dish
May 22, 2018 - FDA Approves Lokelma (sodium zirconium cyclosilicate) for the Treatment of Adults with Hyperkalemia
May 22, 2018 - Making America’s doctors look more like America
May 22, 2018 - Few parents use simple strategies to protect kids from food poisoning, reports study
May 22, 2018 - Reduction in heart disease risk factors could help prevent frailty among older adults
May 22, 2018 - Study finds age-related racial disparities in youth suicide
May 22, 2018 - Childhood leukemia linked to lack of childhood infections
May 22, 2018 - Scientists identify new drug target to combat chikungunya virus
May 22, 2018 - PSCK9 inhibitors may provide benefit to atherosclerosis patients with high lipoprotein(a) levels
Novel drug combination could enhance immunotherapy responses in patients with lung cancer

Novel drug combination could enhance immunotherapy responses in patients with lung cancer

image_pdfDownload PDFimage_print

Johns Hopkins Kimmel Cancer Center researchers and colleagues have identified a novel drug combination therapy that could prime nonsmall cell lung cancers to respond better to immunotherapy. These so-called epigenetic therapy drugs, used together, achieved robust anti-tumor responses in human cancer cell lines and mice.

During the study, published Nov. 30, 2017, in the journal Cell, a team of researchers led by graduate student Michael Topper; research associate Michelle Vaz, Ph.D.; and senior author Stephen B. Baylin, M.D., combined a demethylating drug called 5-azacytidine that chemically reignites some cancer suppressor genes’ ability to operate, with one of three histone deacetylase inhibitor drugs (HDACis). The HDACis work against proteins called histone deacetylases that are involved in processes, such as cell copying and division, and can contribute to cancer development. The combination therapy triggered a chemical cascade that increased the attraction of immune cells to fight tumors and diminished the work of the cancer gene MYC. Based on these findings, investigators have launched a clinical trial of the combination therapy in patients with advanced, nonsmall cell lung cancer.

The development of therapeutic approaches for patients with lung cancer has been a critical medical need, says Baylin, the Virginia and Daniel K. Ludwig Professor of Cancer Research at the Kimmel Cancer Center. While immune checkpoint therapy has been “a tremendous step forward, less than half of patients with lung cancer have benefited to date,” he says.

“In our study, the two-drug epigenetic therapy combination worked exceedingly well, even before putting in the immune checkpoint inhibitors,” Baylin says. “In animal models of lung cancer, the two agents either prevented cancer from emerging or blunted the effects of more aggressive cancers. In both scenarios, a large component of the results involved an increase in immune recognition of the tumors.”

In a series of experiments, researchers studied the combination of 5-azacytidine with the HDACis entinostat, mocetinostat or givinostat in human cancer cell lines and in mouse models of nonsmall cell lung cancers. The treatments were found to alter the tumor microenvironment. In cancer cell lines, 5-azacytidine worked against the cancer gene MYC, causing down regulation of the entire MYC signaling program. Adding the HDACis further depleted MYC, and together the drugs subsequently caused actions that prevented cancer cell proliferation, simultaneously attracted more immune system T cells to the area of the tumor and activated these cells for tumor recognition.

In mouse models, the strongest response was observed when using 5-azacytidine plus givinostat. In one mouse model with a mutant form of nonsmall cell lung cancer, this drug combination given for three months yielded prevention of benign, precursor tumors from becoming cancers and caused 60 percent reduction of overall area of benign tumor appearance in the lungs. By contrast, a group of mice with the same form of lung cancer that were given a mock treatment universally developed large, cancerous lesions in the lungs.

In a second model of mice with established, aggressive, nonsmall cell lung cancer, treatment with an alternating schedule of 5-azacytidine with givinostat and of 5-azacytidine with mocetinostat not only reduced the growth of established, rapidly growing primary tumors but also dramatically reduced metastatic occurrence.

Baylin and colleagues at Memorial Sloan Kettering Cancer Center in New York and Fox Chase Cancer Center in Philadelphia have started a phase I/Ib clinical trial to evaluate if giving mocetinostat with a 5-azacytidinelike drug called guadecitabine can boost immune checkpoint therapy responses in patients with advanced, nonsmall cell lung cancers. The trial is part of the Van Andel Research Institute–Stand Up To Cancer Epigenetics Dream Team and is funded by Merck through the Stand Up To Cancer (SU2C) Catalyst program, an initiative led by SU2C to bring innovative cancer treatments to patients quickly. Matthew Hellmann, M.D., an author on the paper, will lead this trial at Memorial Sloan Kettering, and Jarushka Naidoo, M.B.B.Ch., assistant professor of oncology, will lead at Johns Hopkins.

Source:

https://www.hopkinsmedicine.org/news/media/releases/2_drug_combination_may_boost_immunotherapy_responses_in_lung_cancer_patients

Tagged with:

About author

Related Articles